, 2012 Many differences in clinicopathological features of gastric cancer and its treatment have been reported between the East and the West however such a comparison using Australian data is still lacking. Gastric cancers seen in Australia differ significantly
Kwon, Sebastianus +11 more
core
Avaliação da expressão do peptídeo insulinotrópico dependente de glicose (GIP) e do seu receptor na medula espinal de animais submetidos ao modelo experimental de lesão medular traumática induzida por compressão [PDF]
, 2012 Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Médicas, Florianópolis, 2011A lesão traumática da medula espinal (LTME) desencadeia uma síndrome neurológica altamente ...
Marcos, Ana Beatriz Sperb Wanderley
core
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Tirzepatide-related acute liver injury
European Journal of Case Reports in Internal MedicineTirzepatide, a modified protein containing 39 amino acids, acts as a dual agonist at the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, showing great promise in weight-loss treatment.
Irrum Abdullah +2 more
doaj +1 more source
Cistanche promotes the adipogenesis of 3T3-L1 preadipocytes
PLoS ONE, 2022 Cistanche deserticola Ma (cistanche) is a traditional herb with a wide range of therapeutic properties. However, no evidence of cistanche’s effect on adipogenesis has been found.
Ping Zhang +9 more
doaj
British Journal of Pharmacology, EarlyView.Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley +1 more source
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
British Journal of Pharmacology, EarlyView.Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Phosphorylation Sites of the Gastric Inhibitory Polypeptide Receptor (GIPR) Revealed by Trapped-Ion-Mobility Spectrometry Coupled to Time-of-Flight Mass Spectrometry (TIMS-TOF MS). [PDF]
J Am Chem Soc, 2023 Brown KA +4 more
europepmc +1 more source
Eupatilin Inhibits Gastric Cancer Cell Growth by Blocking STAT3-Mediated VEGF Expression [PDF]
, 2011 Purpose: Eupatilin is an antioxidative flavone and a phytopharmaceutical derived from Artemisia asiatica. It has been reported to possess anti-tumor activity in some types of cancer including gastric cancer.
Yanjun Zheng +5 more
core +1 more source
Amylin analogues as a novel perspective in anti‐obesity therapy
British Journal of Pharmacology, EarlyView.Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source